Directorio

We are doing this study to find out if an investigational drug called teclistamab (the study drug) is a safe and effective option for people who have multiple myeloma and have achieved at least a partial response to standard therapy. We want to know how well it works on its own and in combination with a standard drug called lenalidomide.

We are doing this study to learn more about how brain cell activity guides memory and navigation.

The Endometrial Cancer Molecularly Targeted Therapy Consortium is a multi-institutional alliance that is developing a cancer data and tissue repository. The information in this repository will be used to better understand tumor alterations and cancer biomarkers that can help us develop new therapies and potentially improve survival outcomes for women with endometrial cancer.

We are doing this study to learn more about spasticity that some people experience after they have a stroke. Spasticity is a condition where muscles involuntarily stiffen and aren't as strong as they should be. We want to better understand when this happens after a stroke, what parts of the body are most likely to be affected, and how the symptoms affect people.

In this study, people will get a special shot called a nerve block. It is given in the back of the neck while the person is asleep under general anesthesia. This means they will not feel anything during the procedure.

We are doing this study to keep tabs on the performance of a medical device called TVT Exact. This device is used to help control stress urinary incontinence. We want to know how well this device works long-term in Duke patients who elected to use it.

We are doing this study to find out if an experimental drug called XC001 (the study drug) is an effective option for people who have angina that is caused by coronary artery disease. We want to know if the study drug can provide relief when common, approved therapies have failed to do so. The study drug is made using an adenovirus (one of the causes of the common cold). The adenovirus in the study drug is genetically altered so it is able to deliver a protein called VEGF (vascular endothelial growth factor) to the heart and potentially spur the growth of new blood vessels.